1 Title:

4

- 2 Surveillance of SARS-CoV-2 variants in Argentina: detection of Alpha, Gamma, Lambda,
- 3 Epsilon and Zeta in locally transmitted and imported cases
- 5 Short communication
- 7 Authors:
- 8 Torres Carolina^{1,2,*}, Mojsiejczuk Laura^{1,2,*}, Acuña Dolores^{2,3,*}, Alexay Sofía^{3,*}, Amadio Ariel^{2,4,§},
- 9 Aulicino Paula^{2,5,§}, Debat Humberto^{6,§}, Fernández Franco^{6,§}, Goya Stephanie^{3,§}, König Guido^{7,§},
- Nabaes Jodar Mercedes^{2,3,§}, Pianciola Luis^{8,§}, Bengoa Sofía^{7,#}, Cacciahue Marco^{7,#}, Camussone
- 11 Cecilia^{4,#}, Dus Santos María José^{9,10,#}, Eberhardt María Florencia^{2,4,#}, Fernandez Ailen^{8,#},
- 12 Gismondi María Inés^{7,11,#}, Irazoqui Matías^{2,4,#}, Lusso Silvina^{3,#}, Marquez Nathalie^{6,#}, Muñoz
- 13 Marianne^{12,#}, Natale Mónica^{3,#}, Pisano Belén^{2,13,#}, Puebla Andrea^{12,#}, Re Viviana^{2,13,#}, Sosa
- 14 Ezequiel^{14,#}, Zaiat Jonathan^{14,#}, Zunino Sebastián^{11,15,#}, Do porto Darío^{14,#}, Acevedo María
- 15 Elina^{3,&}, Alvarez Lopez Cristina^{3,&}, Álvarez María Laura^{16,&}, Angeleri Patricia^{17,&}, Angelletti
- Andrés^{18,19,&}, Arca Manuel^{20,&}, Barbas Gabriela^{21,&}, Bertone Ana^{37,&}, Bonnet Agustina^{20,&},
- 17 Bourlot Ignacio^{31,&}, Castello Alejandro^{22,&}, Castro Gonzalo^{23,&}, Ceriani Carolina^{24,&}, Cimino
- 18 Carlos^{25,&}, Cipelli Julián^{3,&}, Colmeiro María^{19,&}, Cordero Andrés^{18,&}, Cristina Carolina^{26,&}, Di Bella
- 19 Sofia^{19,&}, Ercole Regina^{19,&}, Espasandin Yesica^{16,&}, Espul Carlos^{27,&}, Falaschi Andrea^{27,&},
- Fernandez Moll Facundo^{26,&}, Gatelli Andrea^{19,&}, Goñi Sandra^{22,&}, Jofré María Estela^{28,&}, Jaramillo
- 21 José^{15, &}, Labarta Natalia^{3, &}, Lacaze María Agustina^{29, &}, Larreche Rocio^{28, &}, Leiva Viviana^{28, &}, Levin
- 22 Gustavo^{31,&}, Luczak Erica^{32,&}, Mandile Marcelo^{22,&}, Massone Carla^{15,&}, Mazzeo Melina^{8,&},
- 23 Medina Carla^{3,&}, Monaco Belén^{15,&}, Montoto Luciana^{33,&}, Mugna Viviana^{34,&}, Musto
- 24 Alejandra^{32,&}, Ojeda Guillermo^{34,&}, Pintos Carolina^{8,&}, Pozzati Marcia^{35,&}, Rahhal Marilina^{36,&},
- 25 Rechimont Claudia^{37,&}, Remes Lenicov Federico^{38,&}, Rompato Gabriela^{34,&}, Seery Vanesa^{38,&}, Siri
- Leticia^{31,&}, Spina Julieta^{39,&}, Streitenberger Cintia^{3,&}, Suárez Ariel^{40,&}, Suárez Jorgelina^{26,&},
- 27 Sujanski Paula^{17,&}, Talia Juan Manuel^{29,&}, Theaux Clara^{41,&}, Thomas Guillermo^{3,&}, Ticeira
- 28 Marina^{28,&}, Tittarelli Estefanía^{40,&}, Toro Rosana^{18,&}, Uez Osvaldo^{25,&}, Zaffanella María Belén^{39,&},
- 29 Ziehm Cecilia^{8,&}, Zubieta Martin^{36,&}, on behalf of PAIS Consortium[®], Mistchenko Alicia^{3,42},
- 30 Valinotto Laura^{2,3}, Viegas Mariana^{2,3,@}
- *, §, #, & equally contributing authors
- 32 @ corresponding author
- 33 "http://pais.qb.fcen.uba.ar/

- 34 1. Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de
- 35 Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.
- 36 2. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires,
- 37 Argentina.
- 38 3. Laboratorio de Virología, Hospital de Niños Dr. Ricardo Gutiérrez, CABA, Argentina.
- 39 4. Instituto de Investigación de la Cadena Láctea (IDICAL) INTA-CONICET. Ruta 34 km 227,
- 40 Rafaela (2300), Santa Fe, Argentina.
- 41 5. Laboratorio de Biología Celular y Retrovirus. Hospital de Pediatría "Prof. Juan P. Garrahan",
- 42 CABA, Argentina.
- 43 6. Instituto de Patología Vegetal Centro de Investigaciones Agropecuarias Instituto
- 44 Nacional de Tecnología Agropecuaria (IPAVE-CIAP-INTA), Camino 60 Cuadras Km 5,5
- 45 (X5020ICA), Córdoba, Argentina.
- 46 7. Instituto de Biotecnología/Instituto de Agrobiotecnología y Biología Molecular (INTA-
- 47 CONICET), Hurlingham, Buenos Aires, Argentina.
- 48 8. Laboratorio Central ciudad de Neuquén, Ministerio de Salud, Neuquén, Argentina.
- 49 9. Instituto de Virología e Innovaciones Tecnológicas (INTA-CONICET), Hurlingham, Buenos
- Aires, Argentina.
- 51 10. Laboratorio de Diagnóstico-UNIDAD COVID- Universidad Nacional de Hurlingham,
- Hurlingham, Buenos Aires, Argentina.
- 11. Universidad Nacional de Luján, Departamento de Ciencias Básicas, Argentina. Ruta
- Nacional 5 y Av. Constitución, 6700, Luján.
- 55 12. Unidad de Genómica del Instituto de Biotecnología/Instituto de Agrobiotecnología y
- 56 biología Molecular (INTA-CONICET), Hurlingham, Buenos Aires, Argentina.
- 57 13. Instituto de Virología "Dr. J. M. Vanella", Facultad de Ciencias Médicas, Universidad
- 58 Nacional de Córdoba.
- 14. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN),
- 60 CONICET, Ciudad de Buenos Aires, Argentina.
- 61 15. Laboratorio de Virología Molecular, Hospital Blas L. Dubarry de Mercedes, provincia de
- 62 Buenos Aires, Argentina.
- 63 16. Laboratorio del Hospital Zonal Dr. Ramón Carrillo, San Carlos De Bariloche, provincia de Río
- 64 Negro, Argentina
- 65 17. Comité Operativo de Emergencia COVID, Ministerio de Salud de la Ciudad Autónoma de
- 66 Buenos Aires, Argentina.
- 67 18. Laboratorio de salud pública, Facultad de Ciencias Exactas, UNLP, La Plata, Provincia de
- 68 Buenos Aires, Argentina.

- 69 19. Laboratorio de Virologia, HIEAyC "San Juan de Dios", La Plata, provincia de Buenos Aires,
- 70 Argentina.
- 71 20. Laboratorio de Virología del Hospital JJ Urquiza, Concepción del Uruguay, provincia de
- 72 Entre Ríos, Argentina
- 73 21. Secretaria de Prevención y Promoción, Ministerio de Salud de la provincia de Córdoba,
- 74 Argentina.
- 75 22. Plataforma de Servicios Biotecnólogicos; UTTIPP/PSB, Bernal, provincia de Buenos Aires,
- 76 Argentina.
- 77 23. Laboratorio Central de la Provincia de Córdoba, Ministerio de Salud la provincia de
- 78 Córdoba, Argentina.
- 79 24. Laboratorio de Virología de la Facultad de Veterinaria de la Universidad Nacional del
- 80 Centro de la provincia de Buenos Aires (UNCPBA), Tandil, provincia de Buenos Aires,
- 81 Argentina.
- 82 25. Instituto Nacional de Epidemiología "Dr. Jara" (Mar del Plata, provincia de Buenos Aires,
- 83 Argentina.
- 84 26. Centro de Investigaciones Básicas y Aplicadas, UNNOBA, Junín, provincia de Buenos Aires,
- 85 Argentina.
- 86 27. Dirección de epidemiología y Red de Laboratorios del Ministerio de Salud de la provincia
- 87 de Mendoza, Argentina.
- 88 28. Laboratorio de Biología Molecular Bolívar, LABBO, Bolívar, provincia de Buenos Aires,
- 89 Argentina.
- 90 29. Programa Laboratorio de Salud Pública "Dr Dalmiro Pérez Laborda", Ministerio de Salud de
- 91 la provincia de San Luis, Argentina.
- 92 30. Laboratorio De Salud Pública, Ciudad de Mendoza, provincia de Mendoza, Argentina.
- 93 31. Laboratorio de biología molecular del Hospital Centenario, Gualeguaychú, provincia de
- 94 Entre Ríos, Argentina.
- 95 32. Laboratorio del Hospital Interzonal General de Agudos "Evita", Lanús, provincia de Buenos
- 96 Aires, Argentina.
- 97 33. Laboratorio de Biología Molecular Hospital Pedro de Elizalde, Cuidad Autónoma de Buenos
- 98 Aires, Argentina.
- 99 34. Laboratorio Central, ciudad de Santa Fe, provincia de Santa Fe. Argentina.
- 100 35. Laboratorio de Biología Molecular, Hospital Cosme Argerich, Cuidad Autónoma de Buenos
- 101 Aires, Argentina.
- 102 36. Laboratorio de Hospital El Cruce Dr. Néstor C. Kirchner, CEMET, Florencio Varela, provincia
- de Buenos Aires, Argentina.

104 37. Laboratorio de la Dirección de Epidemiología, Santa Rosa, provincia de La Pampa,

105 Argentina.

- 106 38. Instituto de Investigaciones Biomédicas en Retrovirus y Sida, CONICET-UBA, Cuidad
- 107 Autónoma de Buenos Aires, Argentina.
- 108 39. Laboratorio de Biología Molecular. Hospital Dr. Héctor Cura, Olavarría, provincia de
- 109 Buenos Aires, Argentina.
- 40. Departamento de Biología y genética molecular; IACA Laboratorios, Bahía Blanca, provincia
- de Buenos Aires, Argentina.
- 41. Laboratorio de Biología molecular del Hospital General de Agudos Dr. Carlos G. Durand,
- 113 Cuidad Autónoma de Buenos Aires, Argentina.
- 42. Comisión de Investigaciones Científicas de la provincia de Buenos Aires, Argentina.

Abstract

Molecular surveillance of SARS-CoV-2 variants was performed on a total of 2,406 samples from the capital city and nine provinces of Argentina, during 30 epidemiological weeks (EW) that covered the end of the first wave and the beginning of the ongoing second wave of the COVID-19 pandemic in the country (EW 44/2020 to EW 20/2021). The surveillance strategy was mainly based on Sanger sequencing of a Spike coding region that allows the simultaneous identification of signature mutations associated with worldwide circulating variants. In addition, whole SARS-CoV-2 genome sequences were obtained from 456 samples. The main variants found were Gamma, Lambda and Alpha, and to a lesser extent, Zeta and Epsilon. Whereas Gamma dominated in different regions of the country, both Gamma and Lambda prevailed in the most populated area, the metropolitan region of Buenos Aires (MABA), although showing a heterogeneous distribution along this region. This cost-effective surveillance protocol allowed for a rapid response in a limited access to resources scenario, added information on the expansion of the Lambda variant in South America and contributed to the implementation of public health measures to control the disease spread in Argentina.

KEYWORDS: SARS-CoV-2; variants; South America; Argentina; surveillance; Spike sequence

135136

137

138

139

140

141

142

143

144145

146

147

148

149

150

151

152

153

154155

156

157158

159 160

161162

163

164

165

166

167

Main text The emergence of SARS-CoV-2 variants with concerning characteristics to public health has attracted the attention of the scientific community and governments both regionally and globally since the end of 2020. The most relevant variants described so far include: Alpha (lineage B.1.1.7), first detected in the United Kingdom; Beta (lineage B.1.351), initially detected in South Africa; Gamma (lineage P.1, derived from lineage B.1.1.28), initially detected in Manaus, Brazil, and Japan; Delta (lineage B.1.627.2), initially detected in India; Epsilon (lineages B.1.427 and B.1.429), initially detected in California, United States; Zeta (lineage P.2, derived from lineage B.1.1.28), first detected in Rio de Janeiro, Brazil; and Lambda (lineage C.37, derived from B.1.1.1), initially detected in Peru (1). Four of these variants (Alpha to Delta) have been defined as variants of concern (VOC) given their increased transmissibility and other characteristics (1). They have also been associated with an increased risk of hospitalization (2,3) and, in the case of Beta, Gamma and Delta, with a moderate to substantial reduction in neutralizing activity of monoclonal antibodies, convalescent and vaccine sera (4-6). Gamma and Lambda are particularly relevant for Argentinean public health due to their significant presence in the South American region. Importantly, some of these variants share distinct mutations in the Spike protein -several of them in the receptor binding domain (RBD) region- that potentially affect transmissibility, pathogenesis and/or response to vaccination and immune-based therapies. PAIS is the inter-institutional federal consortium of SARS-CoV-2 genomics in Argentina. It was created by the Ministry of Science and Technology to monitor SARS-CoV-2 diversity and evolution in the country, including surveillance of SARS-CoV-2 variants of public health interest (http://pais.qb.fcen.uba.ar/). Between October 26th, 2020 and May 22nd, 2021 (epidemiological week (EW)44/2020 to EW20/2021), molecular surveillance was performed on a total of 2,406 samples from the capital city and nine provinces of the country, including the four most populated districts (Figure 1 and Table 1). This period covers the end of the first wave and the beginning of the ongoing second and largest wave of the COVID-19 pandemic in Argentina (Figure 2). During that period, the frontiers were mostly open for Argentinean residents, but the foreigners had severe restrictions to enter the country as tourists. For this work, samples analyzed included a randomly selected 2.5-10% fraction of the total positive cases weekly detected in different health care centers. Regular sampling from four sentinel laboratories located in the metropolitan area of Buenos Aires (MABA) was performed

along with sporadic sampling from other locations to sum up a total of 1,950 sequences.

169

170

171

172

173

174

175

176

177

178

179

180

181

182 183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

Surveillance strategy was based on Sanger sequencing of a 970bp region of Spike spanning amino acids 428 to 750 (Figure 3) (7). This region allows the identification of signature mutations associated with variants Alpha, Beta, Gamma, Lambda and Delta. Additionally, complete SARS-CoV-2 genome sequences were obtained from 456 samples using the Quick protocol (8) with Oxford Nanopore or Illumina platforms and combined with partial sequences to perform the analysis of 2,406 sequences (Table 1). In this work we show genomic evidence of SARS-CoV-2 local transmission of variants Alpha, Gamma, Lambda, Epsilon and Zeta in Argentina, as well as the detection of mutations Spike_L452R and Spike_E484K in different geographic regions of the country. Alpha was identified in 220 cases. This variant was detected in the city of Buenos Aires (CABA) and in the provinces of Buenos Aires, Córdoba, Entre Ríos, Santa Fe, San Luis, La Pampa and Neuquén. Its frequency in most of the MABA region (CABA plus Great Buenos Aires (GBA)) reached 19.8% (95% CI = 13.3-28.5) in EW 15/2021 (April 11th to 17th) but decreased to 10.9% (95% CI = 5.1-21.2) in EW 20/2021 (May 16^{th} to 22^{nd}) (Tables 1-2 and Figure 2). The phylogenetic analysis of whole genome sequences (including 127 from Argentina, 43 from this work) showed at least 35 independent introductions to the country, being the most related sequences from the USA, Central America, Europe, and the Middle East. Besides, five highly supported groups with at least three Argentinean sequences were observed (Figure 4). The largest group included 53 sequences from the CABA and nine provinces, from north to south of the country, suggesting a widespread local transmission and diversification. Gamma was identified in a total of 499 cases. This variant was detected in the CABA and in the provinces of Buenos Aires, Córdoba, Santa Fe, Entre Ríos, La Pampa, San Luis, Mendoza and Neuquén. Its frequency in the CABA and GBA remained stable at values over 30% since EW 16/2021, reaching 39.1% (95% CI = 28.0-51.3) in the EW 20/2021. The phylogenetic analysis of complete genome sequences (including 238 from Argentina, 50 from this work) showed at least 50 introductions to Argentina, with the most related sequences from Brazil and the USA. Besides, 18 supported groups with at least three Argentinean sequences were observed (Figure 5). The largest one included 72 sequences from the CABA and 14 provinces, from north to south of the country, also suggesting widespread local transmission and diversification (Figure 5.d). Eight sequences from Argentina were located in a separate clade within P.1 (previously named as P.1-like-II, (9)). This clade was formed by sequences from South America only (Brazil, Chile and Argentina) (Figure 5), showing a regional diversification process. Lambda variant showed a continuous increase since EW 7/2021 in the CABA and the GBA. reaching frequencies of 48.4% (95% CI = 36.6-60.4) in the EW 20/2021. Noteworthy, this

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

variant appears to have replaced Alpha variant in the most populated region of the country (Table 2), given that since EW 15/2021, the proportion of cases associated with Alpha decreased while those associated with Lambda increased. These data have contributed to its recent declaration as a global VOI by the WHO (1). The transmission capacity, clinical behavior, and impact on vaccine effectiveness of this VOI will need further studies. However, preliminary studies have shown that the neutralization capacity of convalescent sera from the first wave viruses in Argentina and sera from individuals vaccinated with Sputnik V was not compromised (BBEI, 2021). On the other hand, increased infectivity and resistance to neutralizing antibodies produced by individuals immunized with CoronaVac (SinoVac) and mRNA-1273 (Moderna) vaccines was observed (10,11). In addition, a probable case of coinfection of Alpha and Gamma was identified in a sample from the city of La Plata, and also two other cases of possible coinfection between Alpha and Lambda in the CABA. These cases will be further analyzed. Importantly, the proportion of cases associated with Alpha and Gamma among individuals with no travel history or contact with travelers in CABA and GBA increased from less than 3% in the EW 7/2021-EW 9/2021 to 50.0% (for joint frequencies) in the EW 20/2021, and adding Lambda, they surpassed 98% of the total samples at that EW (Table 2). However, the distribution of variants of epidemiological interest between EW 9/2021 and EW 20/2021 was heterogeneous within the MABA (Figure 6). While North GBA presented a predominance of Gamma (16/39 cases, 41.0%) and 9/39 cases of Lambda (23.1%), west GBA presented a more even distribution of variants, with Lambda in 58/176 cases (33.0%), Gamma in 49/176 cases (27.8%), and Alpha in 34/176 cases (19.3%). Similarly, the CABA presented Lambda in 150/508 cases (29.5%), Gamma in 110/508 cases (21.7%), and Alpha in 67/508 cases (13.2%). On the contrary, south GBA presented a predominance of Lambda (127/253 cases, 50.2%), followed by Gamma in 47/253 cases (18.6%) and Alpha in 10/253 cases (4.0%). Lastly, Great La Plata (GLP) showed a strong predominance of Gamma, counting 43/61 (70.5%). The analysis of the sporadic sampling from several places of the country also revealed a heterogeneous distribution of variants, showing a high proportion of cases associated with different variants and mutations of interest, especially with Gamma in most of the provinces studied (Table 1). Therefore, the major lineages that circulated on the first wave at the beginning of the studied period were almost completely replaced by worldwide and regional emergent variants in a term of few weeks (Figure 2 and Figure 6), as was previously observed in other countries.

term of few weeks (Figure 2 and Figure 6), as was previously observed in other countries.

236

237

238

239

240

241

242

243

244

245

246

247248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

It is worth noting that data about the dynamics of the co-circulation of these highly transmissible variants are limited, given that in most countries only one of them became rapidly dominant and the introduction of a second VOC occurred after the first was already established. However, according to our data from several regions of Argentina, VOCs and VOIs presented similar frequencies in the population at the time of writing this report, which could allow proper comparative analyses of their dynamics, severity, and impact on vaccine effectiveness. Mutations at aa positions 484 and 452 of Spike protein have been associated with possible immune escape and modified affinity to the human receptor and may occur in various newly emerging lineages worldwide (11-14). Both positions are located within the RBM (receptor binding motif). On one hand, the E484K mutation, constitutively present in Beta, Gamma, Zeta, Eta and lota variants, was associated with resistance to neutralization by monoclonal antibodies, convalescent and vaccinated sera (4,12,15-17). On the other hand, mutations at position 452 of the Spike protein, were associated with decreased neutralization by monoclonal antibodies, convalescent and some vaccine sera (12,13). Another important mutation in Spike is P681R, associated with an enhanced viral fusion (18), which was not detected in this work. The E484K mutation - not associated with Beta o Gamma signatures- was found in 138 cases. Most of the samples come from the CABA and the GBA regions from individuals without travel history, suggesting local circulation, at least, since the last week of December 2020, when it was first detected by our surveillance program. Nevertheless, a reduction in its frequency was observed since EW 12/2021 in the CABA and the GBA, being almost completely replaced by VOCs and VOIs of more recent emergence, such as Lambda (Table 2). So far, 53 of 138 cases analyzed by full-length sequencing have been identified as belonging to the Zeta variant through the analysis of the complete genome. For the L452R mutation, a similar replacement has been observed, being occasionally detected in the CABA and the GBA between the EW 1/2021 and the EW 13/2021, but not thereafter. The complete genome analysis of 21 cases allowed to identify the Epsilon variant in 18 cases: one from lineage B.1.429 and 17 from lineage B.1.427. None of the L452R cases detected so far were associated with Delta or Kappa variants. In conclusion, the surveillance strategy implemented over 30 epidemiological weeks in Argentina, based on Spike and complete genome sequencing, allowed to describe the introduction, establishment, and evolution of SARS-CoV-2 variants of interest and concern in the second wave of the COVID-19 pandemic in South America. The main variants found were

Gamma, Lambda and Alpha, in that order, with lower detection of Zeta and Epsilon. This implementation allowed a rapid response in a limited resource access scenario and contributed to the implementation of public health measures to control disease spread.

Table 1. Cumulative cases analyzed in this work from different regions of Argentina.

274

275

276277

278

Region	Area or city	Period	Alpha	Gamma	Lambda	E484K	L452R	Non VOC/VOI	TOTAL
CABA (part of MABA)		2020-10-26 to 2021-05-22	81	121	160	67	10	427	866
GBA (part of MABA)	North	2020-12-21 to 2021-05-21	5	16	10	4	0	32	67
	West	2020-11-28 to 2021-05-22	35	50	59	17	3	108	272
	South	2020-10-26 to 2021-05-22	10	47	138	27	5	163	390
GLP (part of MABA)		2020-11-27 to 2021-04-24	1	43	13	1	2	31	91
MABA	unknown	2021-02-14 to 2021-05-21	3	2	7	0	0	7	19
PBA (outside MABA)	Several cities	2020-11-27 to 2021-05-21	42	44	48	17	3	82	236
Córdoba	Several cities	2020-11-03 to 2021-05-21	18	23	16	4	11	83	155
Santa Fe	Several cities	2020-12-11 to 2021-05-22	9	68	6	0	3	59	145
Entre Ríos	Several cities	2021-05-11 to 2021-05-14	11	20	3	0	0	3	37
La Pampa	Santa Rosa	2021-05-16 to 2021-05-17	1	11	1	0	0	0	13
San Luis	Several cities	2021-04-02 to 2021-04-17	3	14	3	0	0	10	30
Mendoza	General Alvear	2021-03-22 to 2021-04-08	0	15	0	0	0	0	15
Neuquén	Several cities	2021-01-03 to 2021-05-15	1	25	1	0	2	33	62
Rio Negro	Bariloche	2021-12-21 to 2021-03-09	0	0	0	1	0	7	8
TOTAL		2020-10-26 to 2021-05-22	220	499	465	138	39	1045	2406

Note: The total in CABA (n = 866) does not include two co-infections (Alpha/Lambda) and the total in GLP (n = 91) does not include one co-infection (Alpha/Gamma).

CABA: Buenos Aires city. GBA: Great Buenos Aires. GLP: Great La Plata. MABA: Metropolitan area of Buenos Aires. PBA: Buenos Aires province.

Table 2. Frequency of Alpha and Gamma, and mutations E484K and L452R by epidemiological week (EW) 2020-2021 in the Metropolitan Area of Buenos Aires (MABA).

EW	Alpha		Gamma		Lambda		Mutation E484K ³		Mutation L452R ⁴		Non VOC/VOI		Total of sequences ¹
	Frequency (%)	95%Cl ²	Frequency (%)	95%Cl ²	Frequency (%)	95%CI ²	Frequency (%)	95%CI ²	Frequency (%)	95%Cl ²	Frequency (%)	95%Cl ²	
44-51	0,0	-	0,0	-	0,0	-	5,4	2.0-12.3	0,0	-	94,6	87.7-98.0	93
52	0,0	-	0,0	-	0,0	-	1,5	<0.01-8.6	0,0	I	98,5	91.4-100	68
53	0,0	-	0,0	-	0,0		1,5	<0.01-8.9	0,0	ı	98,5	91.1-100	66
1	0,0	-	0,0	-	0,0	-	1,5	<0.01-8.8	1,5	<0.01-8.8	97,0	89.1-99.8	67
2	0,0	-	0,0	-	0,0	-	8,7	2.9-20.9	0,0	-	91,3	79.1-97.1	46
3	0,0	-	0,0	-	3,0	<0.01-16.7	15,2	6.2-31.4	3,0	<0.01-16.7	78,8	62.0-89.6	33
4	0,0	-	0,0	-	0,0	-	14,3	5.8-29.9	0,0	I	85,7	70.1-94.2	35
5	4,4	<0.01-22.7	0,0	-	0,0	-	26,1	12.3-46.8	0,0	=	69,6	48.9-84.6	23
6	0,0	-	0,0	-	0,0	-	19,4	9.5-35.3	2,8	<0.01-15.4	77,8	61.7-88.5	36
7	1,9	<0.01-10.7	0,0	-	9,3	3.6-20.3	18,5	10.2-31.0	1,9	<0.01-10.7	68,5	55.2-79.4	54
8	1,6	<0.01-9.1	0,0	-	12,5	6.2-23.0	14,1	7.4-24.8	0,0	1	71,9	59.8-81.5	64
9	6,7	3.1-13.5	1,0	<0.01-5.8	16,4	10.4-24.7	10,6	5.9-18.1	3,9	1.2-9.8	61,5	51.9-70.3	104
10	7,0	3.2-14.0	2,0	0.1-7.4	18,0	11.6-26.8	14,0	8.4-22.3	4,0	1.2-10.2	55,0	45.2-64.4	100
11	16,7	9.6-27.1	5,6	1.8-13.8	18,1	10.7-28.6	20,8	12.9-31.7	2,8	0.2-10.2	36,1	26.0-47.7	72
12	13,7	8.2-21.9	11,8	6.7-19.6	33,3	24.9-43.0	9,8	5.2-17.3	2,9	0.6-8.7	28,4	20.6-37.9	102
13	18,5	11.4-28.5	16,1	9.5-25.7	40,7	30.7-51.6	3,7	0.8-10.8	1,2	<0.01-7.3	19,8	12.4-29.8	81
14	7,8	3.8-14.9	34,3	25.8-44.0	47,1	37.7-56.7	0,0	-	0,0	1	10,8	6.0-18.4	102
15	19,8	13.3-28.5	32,1	23.9-41.5	38,7	30.0-48.2	2,8	0.6-8.4	0,0	37.0-65.0	6,6	3.0-13.2	106
16	12,0	6.2-21.5	40,0	29.7-51.3	38,7	28.4-50.0	2,7	0.2-9.8	0,0	-	6,7	2.5-15.0	75
17	11,8	6.3-20.5	41,2	31.3-51.8	41,2	31.3-51.8	2,4	0.1-8.7	0,0	-	3,5	0.8-10.3	85
18	4,7	0.4-16.3	32,6	20.4-47.6	58,1	43.3-71.6	0,0	-	0,0	-	4,7	0.4-16.3	43
19	9,5	3.2-22.6	40,5	27.0-55.5	47,6	33.4-62.3	2,4	<0.01-13.4	0,0	-	0,0	-	42
20	10,9	5.1-21.2	39,1	28.0-51.3	48,4	36.6-60.4	0,0	-	0,0	-	1,6	<0.01-9.1	64

¹ Only the cases from the MABA region that did not present a history of travel or close contact with travelers are included; in cases with a known epidemiological link between samples, only one was included in this table.

280

281

282

283

² The adjusted confidence interval of the frequency was estimated by the modified Wald method (19).

³ Includes detections of the E484K mutation that do not belong to sequences with the characteristic combination of mutations of Gamma or Beta variants.

⁴ Includes detections of the L452R mutation that do not belong to sequences with the characteristic combination of mutations of Delta or Kappa variants.

Figures




Figure 1. Location of cases analyzed in this work and pie charts representing the frequency of each variant detected in every region between EW44/2020 to EW20/2021. 1. Buenos Aires city, 2. Great Buenos Aires (North, West, South), 3. Province of Buenos Aires, 4. Province of Córdoba, 5. Province of Santa Fe, 6. Province of Entre Ríos, 7. Province of La Pampa, 8. Province of San Luis, 9. Province of Mendoza, 10. Province of Neuquén, 11. Province of Río Negro.




Figure 2. Number of reported cases by epidemiological week 2020-2021 since the beginning of the molecular surveillance of SARS-CoV-2 variants. Only cases that did not present a history of travel or close contact with travelers are included. Dotted line (mapped to the left y axis) indicates the average number of confirmed COVID-19 cases per week in the Metropolitan Area of Buenos Aires (MABA).




Figure 3. Representation of the amino acid changes in the S gene of SARS-CoV-2 variants of epidemiological interest. Changes indicated in red correspond to those with the greatest potential impact on viral biology or neutralization by antibodies. The location of CDC fragment 29 (codons 428 to 750) used for active surveillance of variants is indicated.




Figure 4 Phylogenetic tree of SARS-CoV-2 whole genome sequences of Alpha (lineage B.1.1.7). Dataset included sequences from Argentina, their best five BLAST hits sequences (against GISAID database on June 2nd 2021), reference sequences of B.1.1.7 lineage, and B.1.1.1 sequences as outgroup. Only the largest group with Argentinean sequences is shown. Phylogenetic analysis was performed using IQ-TREE v. 2.1.2 COVID-edition (20). The SH-like approximate likelihood ratio test (1000 replicates) (21) and Ultrafast bootstrap Approximation (1000 replicates) (22) were used as methods to evaluate the reliability of the groups obtained. The SH-like / UFB values for the relevant groups are indicated for some groups. We gratefully acknowledge the authors from the originating laboratories responsible for obtaining the specimens and the submitting laboratories where genetic sequence data were generated and shared via the GISAID Initiative, on which part of this research is based (Table S1).




Figure 5. Phylogenetic tree of SARS-CoV-2 whole genome sequences of Gamma (lineage P.1). Dataset included sequences from Argentina, their best five BLAST hits sequences (against GISAID database on June 2nd 2021), reference sequences of P.1 lineage, and B.1.1.28 sequences as outgroup. Only selected groups with Argentinean sequences are shown. Phylogenetic analysis was performed as previously described in Figure 5. *P.1-like-I and **P.1-like-II described by Gräf et al (9). We gratefully acknowledge the authors from the originating laboratories responsible for obtaining the specimens and the submitting laboratories where genetic sequence data were generated and shared via the GISAID Initiative, on which part of this research is based (Table S2).




Figure 6. Cumulative number of SARS-CoV-2 variants and sequences with or without mutations of interest in the Metropolitan area of Buenos Aires (CABA, GBA and Great La Plata (GLP)). The cases were analyzed in two periods: until EW 8/2021 and from EW 9/2021 to EW 20/2021, according to the moment of change in the trend of the frequencies of the variants or mutations in each region. Only cases that did not present a history of travel or close contact with travelers are included; in cases sharing an epidemiological link, only one was considered as representative. The bars show the number of samples corresponding to variants, mutations or non-VOC/non-mutations of interest.

References

- 1. WHO. Weekly epidemiological update on COVID-19 15 June 2021 [Internet]. 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021
- 2. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks
 38/2020 to 10/2021. Eurosurveillance [Internet]. 2021;26(16). Available from:
 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348
- Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland:
 demographics, risk of hospital admission, and vaccine effectiveness. Lancet [Internet].
 2021;397(10293):2461–2. Available from: http://dx.doi.org/10.1016/S0140-6736(21)01358 1
 - 4. Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell [Internet]. 2021 Apr 29;184(9):2372-2383.e9. Available from:

- 351 https://doi.org/10.1016/j.cell.2021.03.013
- 352 5. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased Resistance of SARS-
- 353 CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv [Internet]. 2021 Jan
- 354 1;2021.03.01.433466. Available from:
- 355 http://biorxiv.org/content/early/2021/04/09/2021.03.01.433466.abstract
- 356 6. Biobanco de Enfermedades Infecciosas. Seroneutralización de variantes SARS-CoV-2
- 357 Gamma (P.1, Manaos), Alpha (B.1.1.7, Reino Unido) y Lambda (C.37, Andina) en
- 358 individuos vacunados con Sputnik V e individuos recuperados de la infección por SARS-CoV-
- 359 2 [Internet]. 2021. Available from:
- http://pais.qb.fcen.uba.ar/files/reportes/informe_seroneutralizacion_C37_P1.pdf
- 361 7. Paden C, Tao Y, Queen K, Zhang J, Li Y, Uehara A, et al. Rapid, Sensitive, Full-Genome
- 362 Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis J
- 363 [Internet]. 2020;26(10):2401. Available from: https://wwwnc.cdc.gov/eid/article/26/10/20-
- 364 1800_article
- 365 8. Quick J. nCoV-2019 sequencing protocol v3 (LoCost) V.3 [Internet]. 2020. Available from:
- 366 https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye
- 9. Gräf T, Bello G, Martins Venas TM, Cavalcante Pereira E, Dias Paixão AC, Reis Appolinario L,
- et al. Identification of SARS-CoV-2 P.1-related lineages in Brazil provides new insights about
- 369 the mechanisms of emergence of Variants of Concern [Internet]. Available from:
- 370 https://virological.org/t/identification-of-sars-cov-2-p-1-related-lineages-in-brazil-provides-
- 371 new-insights-about-the-mechanisms-of-emergence-of-variants-of-concern/694
- 372 10. Acevedo ML, Alonso-Palomares L, Bustamante A, Gaggero A, Paredes F, Cortés CP, et
- al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda.
- 374 medRxiv [Internet]. 2021 Jan 1;2021.06.28.21259673. Available from:
- 375 http://medrxiv.org/content/early/2021/07/01/2021.06.28.21259673.abstract
- 376 11. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. SARS-CoV-2
- 377 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies
- and Convalescent Serum. bioRxiv [Internet]. 2021 Jan 1;2021.07.02.450959. Available from:
- 379 http://biorxiv.org/content/early/2021/07/03/2021.07.02.450959.abstract
- 380 12. Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE, Stumpf S, et al. Identification
- 381 of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody
- neutralization. Cell Host Microbe. 2021 Mar;29(3):477-488.e4.
- 383 13. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep

- 384 Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on
- Folding and ACE2 Binding. Cell [Internet]. 2020;182(5):1295-1310.e20. Available from:
- https://www.sciencedirect.com/science/article/pii/S0092867420310035
- 387 14. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al.
- Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in
- 389 California carrying a L452R spike protein mutation. medRxiv [Internet]. 2021 Jan
- 390 1;2021.03.07.21252647. Available from:
- 391 http://medrxiv.org/content/early/2021/03/09/2021.03.07.21252647.abstract
- 392 15. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, et al. Escape from
- neutralizing antibodies by SARS-CoV-2 spike protein variants. Marsh M, van der Meer JWM,
- 394 Montefiore D, editors. Elife [Internet]. 2020;9:e61312. Available from:
- 395 https://doi.org/10.7554/eLife.61312
- 396 16. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete Mapping
- of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody
- 398 Recognition. Cell Host Microbe [Internet]. 2021 Jan 13;29(1):44-57.e9. Available from:
- 399 https://doi.org/10.1016/j.chom.2020.11.007
- 400 17. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to
- 401 SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
- 402 Science (80-) [Internet]. 2020 Aug 21;369(6506):1014 LP 1018. Available from:
- http://science.sciencemag.org/content/369/6506/1014.abstract
- 404 18. Saito A, Nasser H, Uriu K, Kosugi Y, Irie T, Shirakawa K, et al. SARS-CoV-2 spike P681R
- 405 mutation enhances and accelerates viral fusion. bioRxiv [Internet]. 2021 Jan
- 406 1;2021.06.17.448820. Available from:
- 407 http://biorxiv.org/content/early/2021/06/17/2021.06.17.448820.abstract
- 408 19. Agresti A, Coull BA. Approximate Is Better than "Exact" for Interval Estimation of
- 409 Binomial Proportions. Am Stat [Internet]. 1998 Jul 14;52(2):119–26. Available from:
- 410 http://www.jstor.org/stable/2685469
- 411 20. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et
- 412 al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic
- 413 Era. Mol Biol Evol [Internet]. 2020 May 1;37(5):1530–4. Available from:
- 414 https://doi.org/10.1093/molbev/msaa015
- 415 21. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms
- and methods to estimate maximum-likelihood phylogenies: assessing the performance of

417 PhyML 3.0. Syst Biol [Internet]. 2010;59(3):307-21. **Available** from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citational Control Citational Control Citational Control Citational Citational418 n&list_uids=20525638 419 420 22. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol [Internet]. 2018 Feb 1;35(2):518-22. 421 422 Available from: https://doi.org/10.1093/molbev/msx281 423 424 425 **Funding**

Proyecto IP COVID-19 N°08, Focem COF 03/11 Covid-19.